Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

Completed · Phase 2

Conditions studied: Pterygium

In brief

Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)

Key facts

Study ID

NCT03049852

Run by

Cloudbreak Therapeutics, LLC

People needed

75

Starts

2017-04-15

Expected to finish

2018-04-30

Last updated by the study team

2020-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary pterygium with moderate vascularity (Pterygium Hyperemia Grading Scale ≥ 3)

You may not qualify if…

• Active ocular disease, corneal abnormalities other than pterygium, active ocular infection, or any ocular pathology unrelated to pterygium in either eye that could affect the assessment of the pterygium
• History of ocular herpes disease in either eye
• Any ocular surgical procedure within the last 3 months
• Female patients who are pregnant, nursing, or planning a pregnancy during the study

Where it is running

• Harvard Eye Associates — Laguna Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.